Progress in the clinical development of CX-2051, targeted at advanced colorectal cancer, with initial Phase 1a clinical data expected in the first half of 2025. CytomX maintains a strong financial ...
- The CTMX-2051-101 study has enrolled 73 colorectal cancer patients to-date, aligned with the Company’s goal of providing a Phase 1 data update in Q1 2026 - - The CTMX-2051-101 study remains active ...
CytomX reports promising Phase 1 data for CX-2051 in advanced colorectal cancer, with planned Phase 2 study in 2026. CytomX Therapeutics announced positive interim results from its Phase 1 study of CX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results